JP2023535598A5 - - Google Patents
Info
- Publication number
- JP2023535598A5 JP2023535598A5 JP2023505412A JP2023505412A JP2023535598A5 JP 2023535598 A5 JP2023535598 A5 JP 2023535598A5 JP 2023505412 A JP2023505412 A JP 2023505412A JP 2023505412 A JP2023505412 A JP 2023505412A JP 2023535598 A5 JP2023535598 A5 JP 2023535598A5
- Authority
- JP
- Japan
- Prior art keywords
- groups
- ligand
- group
- solvate
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010730899 | 2020-07-27 | ||
| CN202010730899.8 | 2020-07-27 | ||
| CN202010735910.X | 2020-07-28 | ||
| CN202010735910 | 2020-07-28 | ||
| PCT/CN2021/108666 WO2022022508A1 (zh) | 2020-07-27 | 2021-07-27 | 抗cd79b抗体药物偶联物、其制备方法及其医药用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535598A JP2023535598A (ja) | 2023-08-18 |
| JP2023535598A5 true JP2023535598A5 (enExample) | 2024-08-27 |
| JP7817236B2 JP7817236B2 (ja) | 2026-02-18 |
Family
ID=80037618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505412A Active JP7817236B2 (ja) | 2020-07-27 | 2021-07-27 | 抗ｃｄ７９ｂ抗体薬物複合体、その調製方法及びその医薬用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230405138A1 (enExample) |
| EP (1) | EP4190812A4 (enExample) |
| JP (1) | JP7817236B2 (enExample) |
| KR (1) | KR20230044275A (enExample) |
| CN (1) | CN115698079A (enExample) |
| AU (1) | AU2021317378A1 (enExample) |
| BR (1) | BR112023001359A2 (enExample) |
| CA (1) | CA3184724A1 (enExample) |
| MX (1) | MX2023001163A (enExample) |
| TW (1) | TWI888610B (enExample) |
| WO (1) | WO2022022508A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3225975A1 (en) * | 2021-07-22 | 2023-01-26 | Shanghai Senhui Medicine Co., Ltd. | Drug conjugate of eribulin derivative |
| CN117881431A (zh) * | 2021-08-24 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
| JP2024533356A (ja) * | 2021-09-16 | 2024-09-12 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 抗ｈｅｒ３抗体薬物複合体及びその組成物並びに用途 |
| WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
| JP2025504419A (ja) * | 2022-01-26 | 2025-02-12 | 上▲海▼▲邁▼晋生物医▲薬▼科技有限公司 | 抗ＣＤ７９ｂ抗体薬物複合体を含む医薬組成物及びその使用 |
| CN118647408A (zh) * | 2022-02-16 | 2024-09-13 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
| JP2025508779A (ja) * | 2022-02-24 | 2025-04-10 | エボポイント、バイオサイエンシズ、カンパニー、リミテッド | 抗体及びその薬物コンジュゲート並びに用途 |
| EP4568997A1 (en) * | 2022-08-08 | 2025-06-18 | ATB Therapeutics | Humanized antibodies against cd79b |
| WO2024078612A1 (en) * | 2022-10-14 | 2024-04-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Linker-payload compound, conjugates and applications thereof |
| CN117917248A (zh) * | 2022-10-20 | 2024-04-23 | 英诺湖医药(杭州)有限公司 | 酶裂解连接子及包含其的配体-艾瑞布林偶联物 |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| TW202542200A (zh) * | 2022-12-29 | 2025-11-01 | 美商Ｌｔｚ治療股份有限公司 | 抗CD79b抗體及其用途 |
| CN120282976A (zh) * | 2023-04-12 | 2025-07-08 | 荣昌生物制药(烟台)股份有限公司 | 一种甲基奥瑞他汀e化合物的制备及纯化方法 |
| WO2025162493A1 (zh) * | 2024-01-29 | 2025-08-07 | 甘李药业股份有限公司 | 抗Nectin-4抗体、配体药物偶联物及其应用 |
| WO2025162364A1 (zh) * | 2024-02-02 | 2025-08-07 | 江苏恒瑞医药股份有限公司 | 抗CD79b抗体药物偶联物联合免疫治疗剂、化疗剂治疗肿瘤 |
| WO2025209279A1 (zh) * | 2024-04-03 | 2025-10-09 | 英诺湖医药(杭州)有限公司 | 一种抗b7h3抗体-艾瑞布林偶联物及其应用 |
| WO2026006252A1 (en) * | 2024-06-25 | 2026-01-02 | Abbvie Inc. | Anti-cd79b antibody drug conjugates |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| AU2016273960B2 (en) * | 2007-07-16 | 2019-01-24 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
| EP2176295B1 (en) * | 2007-07-16 | 2014-11-19 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| KR101607346B1 (ko) | 2008-01-31 | 2016-03-29 | 제넨테크, 인크. | 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법 |
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| CN105189558A (zh) * | 2013-05-02 | 2015-12-23 | 豪夫迈·罗氏有限公司 | 无岩藻糖基化CD20抗体与CD79b抗体-药物缀合物的组合疗法 |
| HUE049175T2 (hu) * | 2014-09-23 | 2020-09-28 | Hoffmann La Roche | Eljárás anti-CD79b immunkonjugátumok alkalmazására |
| ES2744540T3 (es) * | 2014-12-05 | 2020-02-25 | Hoffmann La Roche | Anticuerpos anti-CD79b y procedimientos de uso |
| CA3015098A1 (en) | 2016-02-26 | 2017-08-31 | Jiangsu Hengrui Medicine Co., Ltd. | New toxin and method for preparing intermediate thereof |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| CR20250325A (es) * | 2018-04-13 | 2025-08-29 | Genentech Inc | Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550) |
| WO2020063676A1 (zh) | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| CA3114474A1 (en) | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| CN111116745B (zh) * | 2018-11-01 | 2022-10-14 | 上海新理念生物医药科技有限公司 | 抗CD79b抗体、其药物偶联物及其应用 |
| CN113286823B (zh) * | 2019-01-28 | 2024-05-07 | 上海拓界生物医药科技有限公司 | 抗cd79b抗体、其抗原结合片段及其医药用途 |
| JP7821733B2 (ja) * | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
-
2021
- 2021-07-27 TW TW110127556A patent/TWI888610B/zh active
- 2021-07-27 EP EP21849525.7A patent/EP4190812A4/en active Pending
- 2021-07-27 MX MX2023001163A patent/MX2023001163A/es unknown
- 2021-07-27 AU AU2021317378A patent/AU2021317378A1/en active Pending
- 2021-07-27 US US18/018,241 patent/US20230405138A1/en active Pending
- 2021-07-27 BR BR112023001359A patent/BR112023001359A2/pt unknown
- 2021-07-27 CN CN202180042603.6A patent/CN115698079A/zh active Pending
- 2021-07-27 WO PCT/CN2021/108666 patent/WO2022022508A1/zh not_active Ceased
- 2021-07-27 JP JP2023505412A patent/JP7817236B2/ja active Active
- 2021-07-27 KR KR1020237006821A patent/KR20230044275A/ko active Pending
- 2021-07-27 CA CA3184724A patent/CA3184724A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023535598A5 (enExample) | ||
| RU2476441C2 (ru) | Cd19-связывающие средства и их применение | |
| EP3678700B1 (en) | Compounds for reducing the viscosity of biological formulations | |
| US8889130B2 (en) | Treatment of osteoarthritis and pain | |
| CN102143760B (zh) | 前列腺素e2结合蛋白及其用途 | |
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| JP2023510905A5 (enExample) | ||
| JP2022550851A5 (enExample) | ||
| JP2021059546A (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| JP2024545233A5 (enExample) | ||
| CN102958537A (zh) | TNF-α结合蛋白 | |
| ES2994131T3 (en) | Compositions and methods for treating cancer | |
| JP2025510606A (ja) | Ｂ７ｈ４抗体薬物複合体及びその使用 | |
| JP2023519261A5 (enExample) | ||
| EP4536283A1 (en) | A method for programmatically managing antibody disulfide bonds site-specific modification | |
| CN119546345A (zh) | 使用抗cd22抗体寡核苷酸缀合物治疗癌症的方法 | |
| JP2025508665A5 (enExample) | ||
| JP7594708B1 (ja) | ネクチン４を標的としエキサテカンペイロードを含む抗体薬物コンジュゲート（ａｄｃ） | |
| KR20250048287A (ko) | 새로운 티올 환원제, 제조 방법 및 용도 | |
| EP4344707A1 (en) | New anti-nectin-4 antibody drug conjugates | |
| RU2021110824A (ru) | Конъюгат антитело к b7h3-аналог экзатекана и его применение в медицине | |
| WO2025232773A1 (zh) | 药物组合及其用途 | |
| RU2021135114A (ru) | Конъюгат антитела к b7-h4 и лекарственного средства и его медицинское применение | |
| RU2025113325A (ru) | Конъюгат антитело-лекарственное средство, включающий анти-клаудин-18.2 антитело, и его применение в терапии рака | |
| RU2024124223A (ru) | Конъюгат на основе глюкокортикоидного лекарственного средства |